Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Inclusion Criteria

• •Healthy male and female children who completed the previous four dose vaccination series study (NCT00129129). The age of the child at the 3 post-fourth dose timelines are as follows:
• •* Year 1: 22 to 36 months of age.
• •* Year 3: 44 to 60 months of age.
• •* Year 5: 5 years post-dose 4 +/- 8 weeks
• •Written informed consent obtained from the parent or guardian of the subject.
• •Healthy subjects as established by medical history and clinical examination before entering into the study
• •Having completed the fourth dose vaccination of study Hib-MenCY-TT-005/006